Histogen Inc. (HSTO) |
|
0.925 0.077 (9.09%)
|
06-06 15:34 |
|
Open: |
0.87 |
Pre. Close: |
0.8479 |
|
High:
|
0.93 |
Low:
|
0.87 |
|
Volume:
|
37,403 |
Market Cap:
|
4(M) |
|
|
|
Technical analysis |
as of: 2023-06-06 3:19:30 PM |
|
Short-term rate:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
|
Mid-term rate:
|
|
| Target: |
Six months: 1.22 One year: 1.43 |
| Support: |
Support1: 0.82 Support2: 0.68 |
| Resistance: |
Resistance1: 1.04 Resistance2: 1.22 |
| Pivot: |
0.85 |
| Moving Average: |
MA(5): 0.85 MA(20): 0.84
MA(100): 1  MA(250): 1.43 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 37.2 %D(3): 32.4 |
| RSI: |
RSI(14): 52.9 |
| 52-week: |
High: 4.76 Low: 0.68 |
| Average Vol(K): |
3-Month: 1,029 (K) 10-Days: 29 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ HSTO ] has closed below upper band by 27.6%. Bollinger Bands are 35.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.87 - 0.87 |
0.87 - 0.87 |
|
Low:
|
0.82 - 0.83 |
0.83 - 0.83 |
|
Close:
|
0.84 - 0.85 |
0.85 - 0.86 |
|
Company Description |
|
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California. |
Headline News |
Fri, 12 May 2023
Histogen Inc (HSTO) Stock Loses -1.23% This Week; Should You Buy? - InvestorsObserver
Thu, 11 May 2023
Histogen: Q1 Earnings Snapshot - Chron
Thu, 11 May 2023
Histogen Reports First Quarter 2023 Results and Provides Business Update - Yahoo Finance
Thu, 20 Apr 2023
Histogen Announces Online Publication in the Journal of ... - GlobeNewswire
Mon, 03 Apr 2023
Histogen inks license deal with Johns Hopkins University (NASDAQ ... - Seeking Alpha
Tue, 21 Mar 2023
Histogen Inc (HSTO) has fallen 2.84% Tuesday In Premarket Trading - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
4 (M) |
|
% Held by Insiders
|
3.92e+006 (%) |
|
% Held by Institutions
|
2.8 (%) |
|
Shares Short
|
18 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.329e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-70 |
|
Return on Assets (ttm)
|
705.2 |
|
Return on Equity (ttm)
|
-35.4 |
|
Qtrly Rev. Growth
|
19000 |
|
Gross Profit (p.s.)
|
-94.25 |
|
Sales Per Share
|
-73.95 |
|
EBITDA (p.s.)
|
-1.17925e+006 |
|
Qtrly Earnings Growth
|
1.1 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-12 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.02 |
|
Price to Cash Flow
|
0.35 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
31500 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
